Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading stock research

Loading market dashboard

My Watchlist

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Loading stock research

Unicycive Therapeutics, Inc.

UNCY

HealthcareNASDAQUS

$6.92

-$0.51 (-6.86%)

Overview Financials Analysis Valuation Thesis Ownership Compare AI Report News

UNCY

1Y-0.51 (-6.86%)

Candles, volume, SMA 20, and SMA 50

O 7.41H 7.41L 6.86C 6.92Date Jun 5

UNCY

SMA 20 SMA 50 Vol 1.20MEEarnings dates

Open in Chartsfor further analysis

Business Description

Open for the full company profile when you need deeper context.

ShowHide

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Key Metrics

Quick size, liquidity, and volatility measures for the stock.

Market Cap?$148.72M

Volume?1.17M

Avg Volume?574.72K

52w Range$3.71 - $11.00

Beta?1.73

Price Performance

-12.0%

$7.86 to $6.92

YTD

+19.9%